US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CROWN RESERVE ACQUISITION CORP I

10.18

0.0000

Post-market: 10.190.0100+0.10%16:00 EDT

Volume:11

Turnover:112

Market Cap:227.71M

PE:201.58

High:10.18

Open:10.18

Low:10.18

Close:10.18

52wk High:10.21

52wk Low:9.89

Shares:22.37M

Float Shares:12.35M

Volume Ratio:0.00

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0505

ROE:--

ROA:--

PB:-165.89

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

CalciMedica Announces One-for-Five Reverse Stock Split

Crown Reserve Acquisition Amends Carvix Deal Terms to Align Shareholder Vote Requirements

Crown Reserve Acquisition Swings to Q2 FY26 Profit of $1.35 Million; Six-Month FY26 Net Income Slips to $1.09 Million

Press Release: CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/CRAC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRAC\",,,,,undefined,":{"symbol":"CRAC","market":"US","secType":"STK","nameCN":"CROWN RESERVE ACQUISITION CORP I","latestPrice":10.18,"timestamp":1787947200000,"preClose":10.18,"halted":0,"volume":11,"hourTrading":{"tag":"盘后","latestPrice":10.19,"preClose":10.18,"latestTime":"16:00 EDT","volume":1,"amount":10.19,"timestamp":1787947201632,"change":0.01,"changeRate":0.000982,"amplitude":0},"delay":0,"changeRate":0,"floatShares":12353000,"shares":22368800,"eps":0.0505,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-28 16:00:00 EDT","open":10.18,"high":10.18,"low":10.18,"amount":112,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.0505,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":10.18,"postHourTrading":{"tag":"盘后","latestPrice":10.19,"preClose":10.18,"latestTime":"16:00 EDT","volume":1,"amount":10.19,"timestamp":1787947201632,"change":0.01,"changeRate":0.000982,"amplitude":0},"volumeRatio":0.0026021953927676373},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRAC\",,,,,undefined,":{"symbol":"CRAC","floatShares":12353000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.0026021953927676373,"shares":22368800,"dividePrice":0,"high":10.18,"amplitude":0,"preClose":10.18,"low":10.18,"week52Low":9.89,"pbRate":"-165.89","week52High":10.21,"institutionHeld":0,"latestPrice":10.18,"eps":0.0505,"divideRate":0,"volume":11,"delay":0,"ttmEps":0.0505,"open":10.18,"prevYearClose":9.94,"prevWeekClose":10.21,"prevMonthClose":10.15,"prevQuarterClose":10.11,"fiveDayClose":10.21,"twentyDayClose":10.15,"sixtyDayClose":10.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRAC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-27","symbol":"CRAC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRAC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRAC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRAC","date":"2026-08-28","current":201.584158,"percent":0.86,"low":127.49457,"twenty":128.13077,"median":133.449737,"eighty":133.977728,"high":134.769715,"avg":131.805289,"sd":2.81308,"marketCap":227713875},"quantilePoints":[{"date":"2026-04-10","current":127.62181,"twenty":127.49457,"median":127.49457,"eighty":127.62181,"marketCap":216271875},{"date":"2026-04-17","current":127.74905,"twenty":127.49457,"median":127.62181,"eighty":127.74905,"marketCap":216487500},{"date":"2026-04-24","current":127.93991,"twenty":127.596362,"median":127.74905,"eighty":127.87629,"marketCap":216810937},{"date":"2026-05-01","current":128.13077,"twenty":127.62181,"median":127.78086,"eighty":128.002512,"marketCap":217134375},{"date":"2026-05-08","current":128.133315,"twenty":127.62181,"median":127.87629,"eighty":128.028978,"marketCap":217138687},{"date":"2026-05-15","current":128.25801,"twenty":127.723602,"median":127.971083,"eighty":128.133315,"marketCap":217350000},{"date":"2026-05-22","current":128.51249,"twenty":127.74905,"median":128.00353,"eighty":128.256992,"marketCap":217781250},{"date":"2026-05-29","current":133.449737,"twenty":127.74905,"median":128.00353,"eighty":128.25801,"marketCap":226148062},{"date":"2026-06-05","current":133.449737,"twenty":127.74905,"median":128.13077,"eighty":130.40819,"marketCap":226148062},{"date":"2026-06-12","current":133.449737,"twenty":127.787222,"median":128.133315,"eighty":133.449737,"marketCap":226148062},{"date":"2026-06-18","current":133.581735,"twenty":127.838118,"median":128.19439,"eighty":133.449737,"marketCap":226371750},{"date":"2026-06-26","current":133.383738,"twenty":127.87629,"median":128.25801,"eighty":133.449737,"marketCap":226036218},{"date":"2026-07-02","current":133.515736,"twenty":127.889014,"median":128.25801,"eighty":133.449737,"marketCap":226259906},{"date":"2026-07-10","current":133.581735,"twenty":127.93991,"median":128.383977,"eighty":133.449737,"marketCap":226371750},{"date":"2026-07-17","current":133.724293,"twenty":127.952379,"median":133.251741,"eighty":133.515736,"marketCap":226613332},{"date":"2026-07-24","current":133.845731,"twenty":128.002512,"median":133.383738,"eighty":133.581735,"marketCap":226819125},{"date":"2026-07-31","current":133.977728,"twenty":128.00353,"median":133.449737,"eighty":133.581735,"marketCap":227042812},{"date":"2026-08-07","current":134.241724,"twenty":128.00353,"median":133.449737,"eighty":133.713733,"marketCap":227490187},{"date":"2026-08-14","current":134.373722,"twenty":128.00353,"median":133.449737,"eighty":133.845731,"marketCap":227713875},{"date":"2026-08-21","current":134.637718,"twenty":128.00353,"median":133.449737,"eighty":133.845731,"marketCap":228161250},{"date":"2026-08-28","current":134.373722,"twenty":128.13077,"median":133.449737,"eighty":133.977728,"marketCap":227713875}],"updateTime":1788158180273},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRAC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662085184","title":"CalciMedica Announces One-for-Five Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085184","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085184?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:00","pubTimestamp":1787835600,"startTime":"0","endTime":"0","summary":"CalciMedica’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 31, 2026LA JOLLA, Calif., Aug.  27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352053/0/en/calcimedica-announces-one-for-five-reverse-stock-split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662855742","title":"Crown Reserve Acquisition Amends Carvix Deal Terms to Align Shareholder Vote Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2662855742","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662855742?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:39","pubTimestamp":1787776768,"startTime":"0","endTime":"0","summary":"Crown Reserve Acquisition amends Carvix deal terms to align shareholder vote requirementsCrown Reserve Acquisition Corp. I amended its March 30, 2026 business combination agreement with Carvix.Update ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL2nqB01:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659418891","title":"Crown Reserve Acquisition Swings to Q2 FY26 Profit of $1.35 Million; Six-Month FY26 Net Income Slips to $1.09 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659418891","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659418891?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:45","pubTimestamp":1786567552,"startTime":"0","endTime":"0","summary":"Crown Reserve Acquisition swings to Q2 FY26 profit of $1.35 million; six-month FY26 net income slips to $1.09 millionCrown Reserve Acquisition posted Q2 net income of $1.35 million, driven by $1.55 mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL55WywC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992331","title":"Press Release: CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992331?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"CalciMedica announced a private placement of up to approximately. $49 million in gross proceeds, including approximately $15 million in. upfront gross proceeds. The proceeds are expected to support the. advancement of Auxora and CM5480 as part of the Company's pulmonary. -- Auxora Phase 1b proof-of-concept trial in PAH planned: CalciMedica plans. to evaluate Auxora in a Phase 1b trial in patients with pulmonary. arterial hypertension to generate initial clinical evidence regarding the. effects of CRAC channel inhibition on pulmonary vascular and right. -- CM5480 preclinical and IND-enabling studies advancing: Studies are. ongoing to further characterize the pharmacology, pharmacokinetics, and. safety profile of CM5480, CalciMedica's oral CRAC channel inhibitor. candidate for chronic use in PH. Preclinical data suggest CM5480 may be. differentiated by directly protecting right ventricular function, a key","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TM","CRAC","CALC","AP","LU0256863811.USD","03160","BK4161","LU1989772923.USD","BK4580","LU0320765489.SGD","LU2264538146.SGD","BK4099","LU1989772840.SGD","BK4585","PH","BK4007","LU0208291251.USD","BK4555","LU0070302665.USD","BK4604","LU0256863902.USD","LU0417517546.SGD","BK4006","LU1988902786.USD","LU0211331839.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CRAC\",params:#limit:6,delay:false,,,undefined,":[]}}